Ribo Bio-B Reports Increased Net Loss of RMB 288 Million in 2025 Amid Higher IPO Expenses

On March 25, Ribo Life Science - B (06938) released its annual earnings announcement for the year ended December 31, 2025. The company recorded revenue of 149 million yuan in 2025, an increase of 4.1% compared to 143 million yuan in 2024. The revenue growth was mainly due to increased income generated from the collaboration with Boehringer Ingelheim and the sales of nucleoside monomer-related products by Xingbo Run.

In terms of gross profit, the company's gross profit increased from RMB 131 million in 2024 to RMB 135 million in 2025, representing a 3.3% increase. However, the gross profit margin decreased from 91.7% in 2024 to 90.9%, mainly due to the lower gross profit margin of Xingbo Run’s nucleoside monomer-related products compared to the company’s cooperative service gross profit margin. The company's R&D expenditure was RMB 280 million. Administrative expenses significantly increased by 28.0% from RMB 92.51 million to RMB 118 million, primarily due to the increase in costs related to the company’s listing and consulting service fees.

As of 2025, the company's annual loss reached 288 million yuan, increasing from 281 million yuan in 2024, primarily due to higher listing expenses. Overall, the company’s business segments continue to advance in the R&D of small nucleic acid drugs, particularly in the fields of cardiovascular, metabolic, renal, and liver diseases, showing significant potential for business changes.